Dr. Lamiya Gurbanova is a physician who completed her specialization training in…
View profile →We review our content at regular intervals and update it whenever new research or a change in clinical guidelines requires it.
Overview
What Are Myelodysplastic Syndromes?
Myelodysplastic syndromes (MDS) are a group of blood cancers that begin in the bone marrow, where blood cells are made. Abnormal marrow cells do not develop normally, so the body may make too few healthy red blood cells, white blood cells, or platelets. MDS occurs more often in older adults, but it can affect people of other ages. If you are wondering what is myelodysplastic syndrome, it is best understood as myelodysplastic disease that disrupts normal blood cell production.
Symptoms
Myelodysplastic Syndrome Symptoms
Some people have no noticeable myelodysplastic syndrome symptoms and are diagnosed after a routine complete blood count shows an abnormal result. When symptoms occur, they depend on whether red blood cells, white blood cells, platelets, or several cell types are reduced. Low red blood cells can cause anemia-related symptoms, while low white blood cells or platelets can increase infection or bleeding problems.
- Fatigue may occur when red blood cell levels are low.
- Shortness of breath may develop with anemia or exertion.
- Pale skin can be a sign of reduced red blood cells.
- Frequent infections may occur when white blood cell levels are low.
- Fever may signal an infection and needs prompt medical attention.
- Easy bruising may result from a low platelet count.
- Prolonged bleeding can occur when platelets are too low or do not work normally.
- Pinpoint skin spots called petechiae may appear with low platelets.
Causes
Causes of Myelodysplastic Syndromes
Myelodysplastic syndromes develop when genetic changes in blood-forming stem cells disrupt normal cell maturation. The bone marrow then produces blood cells that are abnormal, do not work properly, or do not survive as expected. These changes may arise over time or, less commonly, be linked to an inherited predisposition.
- Previous chemotherapy can be associated with treatment-related MDS.
- Previous radiation therapy can increase the risk of treatment-related MDS.
- Certain environmental or workplace exposures, including benzene and some industrial chemicals, are associated with MDS.
- Inherited genetic syndromes can predispose a person to abnormal blood cell production.
- Many cases of myelodysplastic disease have no identified cause.
Risk Factors
Risk Factors for Myelodysplastic Syndromes
Factors that cannot be changed
- Older age is associated with a higher likelihood of developing MDS.
- Certain inherited genetic syndromes can increase susceptibility to MDS.
- A personal history of blood or bone marrow disorders may be associated with a higher risk.
Treatment-related and environmental factors
- Previous chemotherapy is linked with some cases of treatment-related MDS.
- Previous radiation therapy may increase the risk of MDS.
- Prolonged exposure to benzene or certain industrial chemicals is associated with increased risk.
Side Effects & Complications
Complications and Treatment Side Effects
- Severe anemia can cause marked fatigue, weakness, and shortness of breath.
- Serious infection can occur when MDS lowers the number of infection-fighting white blood cells.
- Bleeding can become dangerous when platelet counts are very low.
- Iron overload may develop after repeated red blood cell transfusions.
- MDS can progress to acute myeloid leukemia in some people.
Possible treatment side effects
- Nausea can occur with some medicines or chemotherapy.
- Low blood counts may worsen during treatment and increase fatigue, infection, or bleeding risks.
- Treatment-related immune changes can increase the risk of infection.
- Organ toxicity may affect the liver, kidneys, heart, or other organs, depending on the therapy.
- Graft-versus-host disease can occur after an allogeneic stem cell transplant.
- Some treatments may affect fertility when relevant to the person and therapy.
Diagnosis & Staging
Diagnosis and Risk Stratification
- A complete blood count measures red blood cells, white blood cells, and platelets.
- A peripheral blood smear examines the size, shape, and appearance of blood cells.
- Bone marrow aspiration and biopsy evaluate blood-forming cells and the marrow environment.
- Chromosome and molecular testing can identify genetic changes that help classify MDS and estimate risk.
- Clinicians evaluate alternative causes of abnormal blood counts, such as nutritional deficiencies, infection, medicines, or other marrow disorders.
How MDS risk is classified
| Feature | Lower-risk MDS | Higher-risk MDS |
|---|---|---|
| Expected pace | May remain stable or change gradually. | May change more quickly and require closer monitoring. |
| Blood-count problems | Low counts may be manageable with monitoring and supportive care. | Low counts may be more severe or affect several blood cell types. |
| Likelihood of progression | Lower likelihood of progressing to acute myeloid leukemia, although progression remains possible. | Higher likelihood of progression to acute myeloid leukemia. |
| Typical treatment goals | Improve blood counts, reduce symptoms, and maintain quality of life. | Reduce disease activity, prevent progression, and consider intensive treatment when appropriate. |
Treatment Options
Myelodysplastic Syndrome Treatment Options
SUPPORTIVE CARE
Observation, regular blood tests, transfusions, infection treatment, and medicines that support blood cell production can control symptoms and maintain quality of life. Iron overload and transfusion needs may also be monitored.
MEDICINES
Growth factors or targeted medicines may help selected people improve blood counts or reduce transfusion needs. Choice depends on the MDS subtype, genetic findings, and prior treatment.
CHEMOTHERAPY
Disease-modifying medicines or chemotherapy may be used when MDS is higher risk or progressing. These treatments can suppress blood counts and increase infection or other treatment-related risks.
STEM CELL TRANSPLANT
An allogeneic stem cell transplant is the main treatment with potential to provide long-term disease control for some patients. It requires a suitable donor and enough overall health to manage serious risks, including graft-versus-host disease.
Treatment selection depends on risk category, symptoms, blood counts, genetic findings, age, other health conditions, donor availability, and personal goals. Myelodysplastic syndrome treatments may change over time as the disease and response to therapy change.
Treatment planning
Treatment is individualized
A hematology team should review clinical-trial options and balance expected benefit against infection, organ, fertility, and transplant-related risks. Ask how each option fits your goals and overall health.
Outlook and Prognosis
Outlook and Prognosis
MDS may remain stable for years, cause ongoing low blood counts, respond to treatment, or progress more quickly. It is not accurate to describe every case as inevitable “preleukemia,” although some cases do progress to acute myeloid leukemia. Individual outlook cannot be predicted from the diagnosis alone.
- MDS subtype influences how the disease behaves and responds to treatment.
- Blast percentage helps show how many immature blood cells are present in the marrow.
- Chromosome findings can affect risk classification and treatment planning.
- Gene findings may provide information about disease behavior and treatment options.
- Blood counts help show the severity and effects of marrow failure.
- Transfusion needs can reflect the ongoing impact of low blood counts.
- Response to treatment affects the expected course.
- Age and overall health influence treatment choices and tolerance.
Survivorship & Follow-up
Survivorship and Follow-Up
- Periodic blood counts monitor red blood cells, white blood cells, and platelets.
- Repeat bone marrow or molecular testing may be performed when results could guide care.
- Transfusion needs are assessed to manage symptoms and treatment effects.
- Iron overload is monitored in people who receive repeated transfusions.
- Surveillance checks for progression, treatment response, or relapse after treatment.
Follow-up timing depends on the MDS risk level, treatment, response, transplant status, and symptoms. Ongoing care may also include infection prevention, vaccination guidance, rehabilitation, emotional support, and coordination among hematology and other care teams.
Branches
2 topics
Myelodysplastic Syndromes
Hematology
Myelodysplastic Syndromes
Medical Oncology
Symptoms
1 topic
Myelodysplastic Syndromes
Fever
